Reports
Sale
Osteoarthritis Therapeutics Market Share, Growth, Forecast: By Type: Hip Osteoarthritis, Spinal Osteoarthritis, Knee Osteoarthritis, Hand Osteoarthritis, Others; By Drug Class: Analgesics, Corticosteroids, Others; By Doses Form; By Route of Administration, By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Osteoarthritis Therapeutics Market Outlook
The osteoarthritis therapeutics market size was valued at USD 9.13 billion in 2023, driven by the increasing geriatric population across the globe. The market size is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032 to achieve a value of USD 19.35 billion by 2032.
Osteoarthritis Therapeutics: Introduction
Millions of people are suffering from osteoarthritis, which is the most prevalent kind of arthritis. It happens due to damage of the protective cartilage that cushions the ends of the bones. Even though osteoarthritis can harm any joint, it most frequently affects the hands, knees, hips, and spine. While the damage to joints cannot be undone, osteoarthritis symptoms can typically be controlled. The progression of the disease may be slowed down, and pain and joint function may be improved by staying active, maintaining a healthy weight, and obtaining specific therapies.
Osteoarthritis Therapeutics Market Analysis
There have been multiple research studies going on to develop new effective drugs for the treatment of osteoarthritis. The researchers launched a combined safety and preliminary efficacy clinical trial (Phases I and IIa) of R805/CX-011 for the treatment of OA in patients. This clinical trial was followed by their previously successful animal-based trial which was performed on a rat and was concluded to be effective. For this trial, around 70 patients test knee injections of R805/CX-011 will be tested.
This may provide a less expensive alternative, also a less invasive option, which would be easy to administer several times a year, with a high potential of delaying or even reducing the need for surgical procedures, further propelling the market growth. More people would want to get treated with less invasive procedures. Researchers are also trying to test the efficacy of R805/CX-011 to promote tissue regeneration in a range of other conditions, such as pulmonary fibrosis and bone loss. This would further aid the osteoarthritis therapeutics market growth.
The key players in the market are focused on launching new and effective products to curb osteoarthritis discomfort in patients, which is propelling the market growth. For instance, the FDA approved the MISHA Knee System, that is an implantable shock absorber effective in partially reducing load on knee joint. This load reduction is expected to result in reduced pain and preserving functionality of the knee. This device would be implanted subcutaneously during an outpatient-compatible procedure. Such approvals are directly contributing to the market growth.
Osteoarthritis Therapeutics Market Segmentations
Market Breakup by Type
- Hip Osteoarthritis
- Spinal Osteoarthritis
- Knee Osteoarthritis
- Hand Osteoarthritis
- Others
Market Breakup by Drug Class
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Analgesics
- Corticosteroids
- Hyaluronic Acid Injections
- Disease-modifying Osteoarthritis Drugs
- Others
Market Breakup by Doses Form
- Tablets and Capsules
- Injections
- Creams and Gels
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Topical
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
Market Breakup by Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region-7MM
- United States
- EU-4 and the United Kingdom
- Japan
Osteoarthritis Therapeutics Market Overview
The rising geriatric population is a major factor influencing the market growth due to the rising bone related issues in geriatric population. It is very common in older to people to develop such joint issues for example joint pain, discomfort while walking or exercising among other factors. The chances of developing osteoarthritis in women are more in comparison to men after the age of 50. According to WHO, 1 in every 6 people in the world will be aged 60 years of age or over by 2030. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.
With this data, a rise in osteoarthritis case is expected in coming years which is directly contribute to the market growth. The increasing advancements, research and development for drug development are also driving the osteoarthritis therapeutics market growth.
The rising initiatives of investments from both private & government organizations to empower the development of healthcare sector and research facilities are a major factor driving the market growth. There has been a significant rise in demand for cell-based research activities, which is likely to further aid the osteoarthritis therapeutics market share.
Due to rising number of research, more drugs are being developed, more clinical trials for the approval are needed to test the potential and efficacy of such drugs. Therefore, increasing number of drug approvals are anticipated to fuel the growth of the market.
Osteoarthritis Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- Abbive Inc.
- Novartis AG
- Amgen Inc.
- Boehringer Ingelheim International GmbH.
- F. Hoffmann-La Roche Ltd.
- Merck & Co Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- AstraZeneca PL
- Zimmer Biomet
- Stryker Corporation
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Doses Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region-7MM |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Osteoarthritis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Osteoarthritis Epidemiology Analysis-7MM
5.1 Epidemiology Overview (2016-2031)
5.2 United States Osteoarthritis Epidemiology (2016-2031)
5.3 EU-4 and United Kingdom Osteoarthritis Epidemiology (2016-2031)
5.4 Japan Osteoarthritis Epidemiology (2016-2031)
6 Osteoarthritis Therapeutics Market Overview
6.1 Osteoarthritis Therapeutics Market Historical Value (2017-2023)
6.2 Osteoarthritis Therapeutics Market Forecast Value (2024-2032)
7 Osteoarthritis Therapeutics Market Landscape
7.1 Osteoarthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Osteoarthritis Therapeutics: Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Osteoarthritis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Osteoarthritis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Osteoarthritis Therapeutics Market Segmentation
11.1 Osteoarthritis Therapeutics Market by Type
11.1.1 Market Overview
11.1.2 Hip Osteoarthritis
11.1.3 Spinal Osteoarthritis
11.1.4 Knee Osteoarthritis
11.1.5 Hand Osteoarthritis
11.1.6 Others
11.2 Osteoarthritis Therapeutics Market by Drug Class
11.2.1 Market Overview
11.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.2.3 Analgesics
11.2.4 Corticosteroids
11.2.5 Hyaluronic Acid Injections
11.2.6 Disease-modifying Osteoarthritis Drugs
11.2.7 Others
11.3 Osteoarthritis Therapeutics Market by Doses Form
11.3.1 Market Overview
11.3.2 Tablets & Capsules
11.3.3 Injections
11.3.4 Creams and Gels
11.3.5 Others
11.4 Osteoarthritis Therapeutics Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Topical
11.5 Osteoarthritis Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Others
11.6 Osteoarthritis Therapeutics Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospitals Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Osteoarthritis Therapeutics Market by Region-7MM
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.4 Japan
12 United States Osteoarthritis Therapeutics Market
12.1 U.S. Osteoarthritis Therapeutics Market Historical Size (2017-2023)
12.2 U.S. Osteoarthritis Therapeutics Market Forecast Size (2024-2032)
12.3 Market Size by Drug Class
13 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market
13.1 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Forecast Size (2024-2032)
13.3 Market Size by Drug Class
14 Japan Osteoarthritis Therapeutics Market
14.1 Japan Osteoarthritis Therapeutics Market Historical Size (2017-2023)
14.2 Japan Osteoarthritis Therapeutics Market Forecast Size (2024-2032)
14.3 Market Size by Drug Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Abbive Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Amgen Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Boehringer Ingelheim International GmbH.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 F. Hoffmann-La Roche Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Teva Pharmaceutical Industries Ltd.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Sun Pharmaceutical Industries Ltd.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 AstraZeneca PL
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Zimmer Biomet
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Stryker Corporation
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
22 Osteoarthritis Therapeutics - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 9.13 billion in 2023, driven by the increasing geriatric population.
The market is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032, and likely to reach a market value of USD 19.35 billion by 2032.
The rising geriatric population and increasing investments from governments and key players in research and development activities are major factors driving the market growth.
The increasing focus of key players to develop new drugs and other helpful solution to overcome or relieve osteoarthritis in elderly patients is a major trend influencing the market growth.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom.
There are hip osteoarthritis, spinal osteoarthritis, knee osteoarthritis, and hand osteoarthritis, among others.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs), analgesics, corticosteroids, hyaluronic acid injections, disease-modifying osteoarthritis drugs, among others are all used to treat Osteoarthritis.
Various forms of dosage are tablets and capsules, injections, creams and gels, among others.
Different routes of administration include oral, parenteral, and topical.
Different end users in the market include hospitals, specialty clinics, and homecare settings, among others.
Different distribution channels in the market include hospitals pharmacy, retail pharmacy, and online pharmacy, among other pharmacies.
Key players involved in the market are Pfizer Inc., Abbive Inc., Novartis AG, Amgen Inc. Boehringer Ingelheim International GmbH., F. Hoffmann-La Roche Ltd., Merck & Co Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PL, Zimmer Biomet, and Stryker Corporation.
Key players involved in the market are Pfizer Inc., Abbive Inc., Novartis AG, Amgen Inc. Boehringer Ingelheim International GmbH., F. Hoffmann-La Roche Ltd., Merck & Co Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PL, Zimmer Biomet, and Stryker Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER